Randomized Treatment Interruption of Natalizumab.
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2016
At a glance
- Drugs Natalizumab (Primary) ; Glatiramer acetate; Interferon beta-1a; Methylprednisolone
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms RESTORE
- Sponsors Biogen
- 17 Sep 2016 Results of this and other four trials assessing relationship of natalizumab exposure and MRI response presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 28 Mar 2014 Results published in the Neurology.
- 23 Mar 2013 Biomarker results presented at the 65th Annual Meeting of the American Academy of Neurology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History